Published in Cancer Res on February 08, 2011
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. Cancer Res (2015) 1.70
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy. Nature (2016) 1.60
Estrogen Receptor β2 Induces Hypoxia Signature of Gene Expression by Stabilizing HIF-1α in Prostate Cancer. PLoS One (2015) 1.48
Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res (2013) 1.26
The 5 alpha-reductase isozyme family: a review of basic biology and their role in human diseases. Adv Urol (2011) 1.14
Adaptation or selection--mechanisms of castration-resistant prostate cancer. Nat Rev Urol (2012) 1.10
Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci Rep (2013) 1.09
AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol (2013) 1.09
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res (2014) 1.07
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor. Mol Cell Endocrinol (2012) 1.01
Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. Steroids (2013) 0.97
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Prostate cancer-from steroid transformations to clinical translation. Nat Rev Urol (2012) 0.93
Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment. Int J Biol Sci (2014) 0.93
Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum. J Steroid Biochem Mol Biol (2013) 0.92
Silibinin inhibits aberrant lipid metabolism, proliferation and emergence of androgen-independence in prostate cancer cells via primarily targeting the sterol response element binding protein 1. Oncotarget (2014) 0.92
Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoS One (2013) 0.89
Steroid hormone synthetic pathways in prostate cancer. Transl Androl Urol (2013) 0.89
Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model. EJNMMI Res (2013) 0.88
A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem (2012) 0.88
Melanoma antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers. J Biol Chem (2012) 0.87
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs (2014) 0.86
In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3). Invest New Drugs (2014) 0.86
Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci (2014) 0.85
Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities? Int J Biol Sci (2014) 0.84
Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. PLoS One (2012) 0.82
High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy. Prostate (2013) 0.82
In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells. Biomed Res Int (2014) 0.80
The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Curr Drug Targets (2013) 0.80
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC). J Steroid Biochem Mol Biol (2015) 0.80
Advanced prostate cancer - patient survival and potential impact of enzalutamide and other emerging therapies. Ther Clin Risk Manag (2014) 0.80
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer. Cancers (Basel) (2016) 0.79
More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer. Asian J Androl (2013) 0.78
Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer (2016) 0.78
Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models. PLoS One (2017) 0.75
Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncol (2016) 0.75
Inhibition of AKR1C3 activation overcomes resistance to abiraterone in advanced prostate cancer. Mol Cancer Ther (2016) 0.75
Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J Med Chem (2016) 0.75
Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget (2016) 0.75
Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int (2014) 0.75
AR-Signaling in Human Malignancies: Prostate Cancer and Beyond. Cancers (Basel) (2017) 0.75
Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action. Database (Oxford) (2016) 0.75
Sex steroid metabolism in benign and malignant intact prostate biopsies: individual profiling of prostate intracrinology. Biomed Res Int (2014) 0.75
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol (2008) 10.91
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Nutrient-sensitive mitochondrial NAD+ levels dictate cell survival. Cell (2007) 6.47
Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med (1995) 6.26
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res (2008) 5.79
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res (2001) 4.12
Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem (1994) 3.87
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res (2001) 3.37
Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res (2002) 3.26
Male pseudohermaphroditism caused by mutations of testicular 17 beta-hydroxysteroid dehydrogenase 3. Nat Genet (1994) 2.35
CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res (1996) 2.18
Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol (1997) 1.90
Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res (2005) 1.84
Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol (1984) 1.79
Identification of the major oxidative 3alpha-hydroxysteroid dehydrogenase in human prostate that converts 5alpha-androstane-3alpha,17beta-diol to 5alpha-dihydrotestosterone: a potential therapeutic target for androgen-dependent disease. Mol Endocrinol (2005) 1.63
Expression and characterization of recombinant type 2 3 alpha-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3 alpha/17 beta-HSD activity and cellular distribution. Mol Endocrinol (1997) 1.59
Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev (1997) 1.53
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem (2007) 1.47
The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res (2004) 1.38
Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol (2006) 1.38
The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest (1976) 1.38
Expression cloning and characterization of oxidative 17beta- and 3alpha-hydroxysteroid dehydrogenases from rat and human prostate. J Biol Chem (1997) 1.33
Transcript profiling of the androgen signal in normal prostate, benign prostatic hyperplasia, and prostate cancer. Endocrinology (2006) 1.27
Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res (2009) 1.14
Broadened ligand responsiveness of androgen receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. Int J Cancer (2002) 1.13
Isolation and characterization of a novel cDNA encoding a human UDP-glucuronosyltransferase active on C19 steroids. J Biol Chem (1996) 1.12
The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol (1990) 1.11
Elucidation of a complete kinetic mechanism for a mammalian hydroxysteroid dehydrogenase (HSD) and identification of all enzyme forms on the reaction coordinate: the example of rat liver 3alpha-HSD (AKR1C9). J Biol Chem (2007) 1.10
Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res (2010) 1.07
Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol (2002) 1.06
Prostate formation in a marsupial is mediated by the testicular androgen 5 alpha-androstane-3 alpha,17 beta-diol. Proc Natl Acad Sci U S A (2000) 1.02
Further characterization of human microsomal 3alpha-hydroxysteroid dehydrogenase. Arch Biochem Biophys (2001) 1.01
Amino-terminus domain of the androgen receptor as a molecular target to prevent the hormonal progression of prostate cancer. J Cell Biochem (2006) 0.98
Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol Hum Reprod (2007) 0.98
Prostate cancer stromal cells and LNCaP cells coordinately activate the androgen receptor through synthesis of testosterone and dihydrotestosterone from dehydroepiandrosterone. Endocr Relat Cancer (2009) 0.95
Identification of the molecular switch that regulates access of 5alpha-DHT to the androgen receptor. Mol Cell Endocrinol (2007) 0.94
Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol (1974) 0.93
Pan1b (17betaHSD11)-enzymatic activity and distribution in the lung. Mol Cell Endocrinol (2001) 0.93
Oxidative 3alpha-hydroxysteroid dehydrogenase activity of human type 10 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol (2003) 0.91
Expression and regulation of steroid 5 alpha-reductase 2 in prostate disease. J Urol (1994) 0.90
3Alpha-androstanediol kinetics in man. J Clin Invest (1974) 0.89
Atmospheric pressure photoionization tandem mass spectrometry of androgens in prostate cancer. Anal Chem (2010) 0.88
Enzymes of androgen formation and degradation in the human prostate. Ann N Y Acad Sci (1990) 0.86
Role of the alternate pathway of dihydrotestosterone formation in virilization of the Wolffian ducts of the tammar wallaby, Macropus eugenii. Endocrinology (2006) 0.85
Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. J Steroid Biochem Mol Biol (1995) 0.84
3 Alpha-hydroxysteroid oxidoreductase activities in dihydrotestosterone degradation and back-formation in rat prostate and epididymis. J Steroid Biochem Mol Biol (1996) 0.82
Non-traditional metabolic pathways of adrenal steroids. Rev Endocr Metab Disord (2009) 0.81
Steroid 5 alpha-reductase type 1 immunolocalized in the adrenal gland of normal, gonadectomized, and sex hormone-supplemented rats. Histochem Cell Biol (1998) 0.81
Naturally occurring progesterone in loblolly pine (Pinus taeda L.): a major steroid precursor of environmental androgens. Environ Toxicol Chem (2008) 0.80
Kinetic analysis of androstenedione 5 alpha-reductase in epithelium and stroma of human prostate. Steroids (1998) 0.78
The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 6.67
Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res (2005) 5.04
Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Mol Cell (2004) 2.38
Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am J Respir Crit Care Med (2011) 2.15
Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertension-induced renal injury in mice. FASEB J (2010) 1.82
Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest (2011) 1.74
Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem (2003) 1.73
Beta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcription. Mol Cell Biol (2003) 1.64
International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev (2006) 1.60
The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem (2002) 1.57
Complete Plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest (2012) 1.52
Immunological identification of the heart myoglobin radical formed by hydrogen peroxide. Free Radic Biol Med (2002) 1.52
Identification of human whole saliva protein components using proteomics. Proteomics (2004) 1.51
HMGB1 is a cofactor in mammalian base excision repair. Mol Cell (2007) 1.49
Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res (2005) 1.49
Endothelial CYP epoxygenase overexpression and soluble epoxide hydrolase disruption attenuate acute vascular inflammatory responses in mice. FASEB J (2010) 1.48
Modulation of androgen receptor activation function 2 by testosterone and dihydrotestosterone. J Biol Chem (2007) 1.47
Convergence of pontine and proprioceptive streams onto multimodal cerebellar granule cells. Elife (2013) 1.45
Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem (2002) 1.41
Melanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interaction. Mol Cell Biol (2005) 1.40
Characterization of glycopeptides from HIV-I(SF2) gp120 by liquid chromatography mass spectrometry. J Am Soc Mass Spectrom (2004) 1.37
An androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of the Hsp70-interacting protein (CHIP). J Biol Chem (2004) 1.36
Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemia-reperfusion injury in isolated mouse heart. FASEB J (2011) 1.33
Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem (2008) 1.32
Frequent aneuploidy among normal human hepatocytes. Gastroenterology (2011) 1.30
Liganded androgen receptor interaction with beta-catenin: nuclear co-localization and modulation of transcriptional activity in neuronal cells. J Biol Chem (2002) 1.28
Identification of the anti-inflammatory protein tristetraprolin as a hyperphosphorylated protein by mass spectrometry and site-directed mutagenesis. Biochem J (2006) 1.26
Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol (2003) 1.24
Elucidation of O-glycosylation structures of the beta-amyloid precursor protein by liquid chromatography-mass spectrometry using electron transfer dissociation and collision induced dissociation. J Proteome Res (2009) 1.24
Identification of free radicals on hemoglobin from its self-peroxidation using mass spectrometry and immuno-spin trapping: observation of a histidinyl radical. J Biol Chem (2003) 1.22
A regulatory network for coordinated flower maturation. PLoS Genet (2012) 1.20
Optimising echocardiographic screening for rheumatic heart disease in New Zealand: not all valve disease is rheumatic. Cardiol Young (2011) 1.18
Steroid receptor coactivator expression throughout the menstrual cycle in normal and abnormal endometrium. J Clin Endocrinol Metab (2002) 1.16
5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate (2010) 1.15
Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP. Mol Cancer Res (2009) 1.14
Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol (2007) 1.13
Protein oxidation of cytochrome C by reactive halogen species enhances its peroxidase activity. J Biol Chem (2002) 1.13
Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol Cell Biol (2009) 1.12
A new small molecule inhibitor of estrogen receptor alpha binding to estrogen response elements blocks estrogen-dependent growth of cancer cells. J Biol Chem (2008) 1.10
The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab (2002) 1.09
Identification of the myoglobin tyrosyl radical by immuno-spin trapping and its dimerization. Free Radic Biol Med (2005) 1.09
Immuno-spin trapping of a post-translational carboxypeptidase B1 radical formed by a dual role of xanthine oxidase and endothelial nitric oxide synthase in acute septic mice. Free Radic Biol Med (2008) 1.08
Electron transfer between a tyrosyl radical and a cysteine residue in hemoproteins: spin trapping analysis. J Am Chem Soc (2007) 1.08
Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A (2013) 1.08
Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis (2012) 1.07
Quantitative proteomics analysis of macrophage rafts reveals compartmentalized activation of the proteasome and of proteasome-mediated ERK activation in response to lipopolysaccharide. Mol Cell Proteomics (2008) 1.07
Epidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptor. Mol Cell Biol (2008) 1.07
Distinct actions of Akt1 and Akt2 in skeletal muscle differentiation. J Cell Physiol (2009) 1.05
Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. J Biol Chem (2005) 1.04
Lysyl hydroxylase 3-mediated glucosylation in type I collagen: molecular loci and biological significance. J Biol Chem (2012) 1.03
An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy. J Biol Chem (2010) 1.03
Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J Am Soc Mass Spectrom (2007) 1.02
Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin Cancer Res (2011) 1.02
Analysis of the oxidative damage-induced conformational changes of apo- and holocalmodulin by dose-dependent protein oxidative surface mapping. Biophys J (2006) 1.02
Site-specific radical formation in DNA induced by Cu(II)-H₂O₂ oxidizing system, using ESR, immuno-spin trapping, LC-MS, and MS/MS. Free Radic Biol Med (2011) 1.02
Proteomic profiling of S-acylated macrophage proteins identifies a role for palmitoylation in mitochondrial targeting of phospholipid scramblase 3. Mol Cell Proteomics (2011) 1.02
CEBS object model for systems biology data, SysBio-OM. Bioinformatics (2004) 1.02
Identification of protein-derived tyrosyl radical in the reaction of cytochrome c and hydrogen peroxide: characterization by ESR spin-trapping, HPLC and MS. Biochem J (2002) 1.02
Research resource: Genome-wide mapping of in vivo androgen receptor binding sites in mouse epididymis. Mol Endocrinol (2010) 1.01
Immuno-spin trapping of protein and DNA radicals: "tagging" free radicals to locate and understand the redox process. Free Radic Biol Med (2009) 1.01
Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators. J Biol Chem (2009) 1.01
Lysyl hydroxylase 3 glucosylates galactosylhydroxylysine residues in type I collagen in osteoblast culture. J Biol Chem (2011) 1.01
Photoaffinity labeling combined with mass spectrometric approaches as a tool for structural proteomics. Expert Rev Proteomics (2006) 1.00
Identification of protein radicals formed in the human neuroglobin-H2O2 reaction using immuno-spin trapping and mass spectrometry. Biochemistry (2008) 1.00
Hormone control and expression of androgen receptor coregulator MAGE-11 in human endometrium during the window of receptivity to embryo implantation. Mol Hum Reprod (2007) 0.98
Identification of all classes of spin-trapped carbon-centered radicals in soybean lipoxygenase-dependent lipid peroxidations of omega-6 polyunsaturated fatty acids via LC/ESR, LC/MS, and tandem MS. Free Radic Biol Med (2003) 0.98
Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol (2011) 0.97
Alterations in the rat serum proteome during liver injury from acetaminophen exposure. J Pharmacol Exp Ther (2006) 0.97
Transcriptional synergy between melanoma antigen gene protein-A11 (MAGE-11) and p300 in androgen receptor signaling. J Biol Chem (2010) 0.97
Two-dimensional electrophoresis study of in vitro pellicle formation and dental caries susceptibility. Eur J Oral Sci (2006) 0.97
Determination of protein-derived epitopes by mass spectrometry. Expert Rev Proteomics (2005) 0.97
DNA binding by yeast Mlh1 and Pms1: implications for DNA mismatch repair. Nucleic Acids Res (2003) 0.96
DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11. Epigenetics (2013) 0.96
Rapid identification of oxidation-induced conformational changes by kinetic analysis. Rapid Commun Mass Spectrom (2007) 0.95
Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction. Mech Ageing Dev (2004) 0.95
Insulin-like growth factor (IGF) binding protein-5 blocks skeletal muscle differentiation by inhibiting IGF actions. Mol Endocrinol (2007) 0.95
Peptidomic analysis of human acquired enamel pellicle. Biomed Chromatogr (2007) 0.95
Domain interactions between coregulator ARA(70) and the androgen receptor (AR). Mol Endocrinol (2002) 0.95
Top-down and bottom-up mass spectrometric characterization of human myoglobin-centered free radicals induced by oxidative damage. Anal Chem (2007) 0.94
Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis (2013) 0.94
A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor {alpha}. J Biol Chem (2010) 0.94
Subcellular proteomics of mice gastrocnemius and soleus muscles. Anal Biochem (2007) 0.93
Immunological detection of N-formylkynurenine in oxidized proteins. Free Radic Biol Med (2009) 0.93
New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res (2013) 0.92